Definium Therapeutics (DFTX) Accumulated Expenses (2020 - 2026)

Definium Therapeutics (DFTX) has reported Accumulated Expenses for 7 consecutive years, with $7.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 35.52% year-over-year to $7.4 million; the TTM figure through Mar 2026 stood at $7.4 million (down 35.52% YoY), while the FY2025 annual figure was $9.5 million, up 47.81% from the prior year.
• Accumulated Expenses fell to $7.4 million in Q1 2026 per DFTX's latest filing, from $9.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $19.0 million in Q3 2025 and bottomed at $3.2 million in Q4 2022.
• Historically, Accumulated Expenses has averaged $9.0 million across 5 years, with a median of $8.2 million in 2024.
• On a YoY basis, Accumulated Expenses climbed as much as 263.79% in 2023 and fell as far as 53.1% in 2023.
• Definium Therapeutics' Accumulated Expenses stood at $3.2 million in 2022, then jumped by 263.79% to $11.6 million in 2023, then tumbled by 44.95% to $6.4 million in 2024, then surged by 47.81% to $9.5 million in 2025, then retreated by 21.7% to $7.4 million in 2026.
• Business Quant data shows DFTX's Accumulated Expenses at $7.4 million in Q1 2026, $9.5 million in Q4 2025, and $19.0 million in Q3 2025.